The scrip opened at Rs. 291.00 and has touched a high and low of Rs. 303.80 and Rs. 291.00 respectively. So far 46089 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 304.75 on 16-Sep-2019 and a 52 week low of Rs. 183.25 on 28-Jan-2019.
Last one week high and low of the scrip stood at Rs. 303.80 and Rs. 277.40 respectively. The current market cap of the company is Rs. 3770.74 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.81% and 32.19% respectively.
Suven Life Sciences has declared dose administration of the first patient in a Phase 2A clinical trial of SUVN G-3031, a Histamine H3 receptor inverse agonist in a Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients with Narcolepsy with or without Cataplexy.
The clinical development program being executed through Suven Neurosciences, Inc., a Delaware Company in USA, wholly owned subsidiary of Suven Life Sciences.
Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.